Zydus Lifes rises after receiving approval from COFEPRIS for Trastuzumab biosimilar
Zydus Lifesciences advanced 1.88% to Rs 1241.60 after the company announced the receipt of marketing approval for Mamitra, a Trastuzumab biosimilar, from the Mexican regulatory authority COFEPRIS.